MA09-hRPE
Sponsors
Astellas Institute for Regenerative Medicine, CHABiotech CO., Ltd
Conditions
Age-Related Macular DegenerationDry Age Related Macular DegenerationStargardt's Macular Dystrophy
Phase 1
Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration
CompletedNCT01344993
Start: 2011-06-09End: 2015-08-19Updated: 2024-10-31
Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy
CompletedNCT01345006
Start: 2011-06-16End: 2015-08-10Updated: 2024-10-31
Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
CompletedNCT01469832
Start: 2011-12-13End: 2015-09-30Updated: 2024-10-31
Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)
CompletedNCT01625559
Start: 2012-09-30End: 2015-04-30Updated: 2024-04-10
A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD
TerminatedNCT01674829
Start: 2012-09-30End: 2017-09-30Updated: 2024-04-09
Unknown Phase
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients
CompletedNCT02445612
Start: 2012-07-11End: 2019-06-21Updated: 2024-10-31
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD
CompletedNCT02463344
Start: 2013-02-25End: 2019-08-19Updated: 2024-10-31